Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644039 · ClinicalTrials.gov registry record · Phase 1
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
A Phase 1 study, sponsored by PharmaMar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT07644039: Recruiting Phase 1 study, sponsored by PharmaMar.
NCT07644039 is a Phase 1 study that is actively recruiting participants, run by PharmaMar. The registered enrollment target is 119 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07644039, a Phase 1 study, is actively recruiting participants, sponsored by PharmaMar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Interventions
- DRUG Pembrolizumab
- DRUG PM54
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2029-04-02 |
| Phase | Phase 1 |
What NCT07644039 shows while recruiting
NCT07644039 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07644039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07644039 about?
NCT07644039 is a clinical study titled "Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies". The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investig...
What is the current status of trial NCT07644039?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2026-05-21. Estimated completion is 2029-04-02.
What interventions are being tested in trial NCT07644039?
The interventions under investigation include: Pembrolizumab (DRUG), PM54 (DRUG).
Who is sponsoring clinical trial NCT07644039?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07644039's enrollment target sits among peer trials
119 498th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI